Compare SNDX & DRH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SNDX | DRH |
|---|---|---|
| Founded | 2005 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.9B |
| IPO Year | 2016 | 2005 |
| Metric | SNDX | DRH |
|---|---|---|
| Price | $21.32 | $10.03 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 13 | 9 |
| Target Price | ★ $80.23 | $9.81 |
| AVG Volume (30 Days) | 1.2M | ★ 3.2M |
| Earning Date | 03-02-2026 | 02-26-2026 |
| Dividend Yield | N/A | ★ 3.36% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.26 |
| Revenue | $111,304,000.00 | ★ $1,125,008,000.00 |
| Revenue This Year | $617.40 | N/A |
| Revenue Next Year | $115.70 | $2.30 |
| P/E Ratio | ★ N/A | $36.97 |
| Revenue Growth | ★ 595.65 | 0.95 |
| 52 Week Low | $8.58 | $6.19 |
| 52 Week High | $22.73 | $9.83 |
| Indicator | SNDX | DRH |
|---|---|---|
| Relative Strength Index (RSI) | 55.53 | 65.85 |
| Support Level | $20.00 | $9.39 |
| Resistance Level | $21.89 | $9.73 |
| Average True Range (ATR) | 1.07 | 0.27 |
| MACD | 0.00 | 0.04 |
| Stochastic Oscillator | 68.62 | 100.00 |
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.
Diamondrock Hospitality Company is a real estate investment trust that owns lodging properties. Its business is to acquire, own, manage, and renovate full-service hotel properties in the United States. It operates in cities such as Chicago, Boston, New York, Denver, and others. Within DiamondRock's holdings, the majority of the hotel brands include Marriott, Starwood, and Hilton. The revenue is divided between room, food and beverage, and others. The room segment contributes the majority of the revenue. The firm's customers include leisure transients, business transients, and group customers.